BGNE: BeiGene Ltd. Company Value to Net Income

BeiGene Ltd. - graphic logo of issuer BGNE

BeiGene, Ltd. (BGNE) is modernizing its biopharmaceutical facilities by implementing water purification systems and green energy. The business's profitability relies on the global sale of proprietary drugs against solid tumors and leukemias. The linear price action on the GURU.Markets chart, where the indicator stands at 47.20, confirms the asset's status as a cash cow due to multi-year patent protection and consistently high demand for targeted therapy.

Price to Earnings Ratio: BeiGene, Ltd. (BGNE) for 07/04/2022 - 11/16/2026

Comprehensive metric breakdowns and analytics for BeiGene Ltd. (BGNE)

- market capitalization information:
Summary company analysis:BeiGene
Flagship merchandise of BeiGene

The multiple is calculated as the ratio of BeiGene, Ltd. (BGNE) market capitalization to its annual net income. This coefficient reflects the fundamental value of the business relative to generated income, signaling whether the asset is overvalued or undervalued. For a company in an expansion phase, it accounts for growth expectations for oncology drug sales in the US and Asia. Analyzing the company's price-to-earnings ratio allows for the identification of entry points. The dynamics of this indicator determine the investment attractiveness of the shares.

Key competitors

ONC: Company Value to Net Income|Price to Earnings Ratio HALO (Halozyme Inc.)|RVMD (RevMed) - Company Value to Net Income|P/E Multiple AAPG (ascentage.com)|CGON - Price to Earnings Ratio|URGN: Price to Earnings Ratio|BCAX - P/E Multiple|Personalis Corp (PSNL) - Price to Earnings Ratio|Erasca Corp - Company Value to Net Income|DCTH (Delcath Systems Inc) - P/E Multiple|Market Cap to Earnings Y-mAbs Therapeutics, Inc. YMAB|P/E Multiple AURA|Price to Earnings Ratio Candel Therapeutics, Inc. CADL|P/E Multiple ARAY (Accuray, Inc.)|SELLAS Life Sciences - Price to Earnings Ratio|ACTU: Price to Earnings Ratio|Citius Oncology, Inc. - Market Price to Net Income Ratio|HURA (TuHURA Biosciences) - Price to Earnings Ratio|TARA: Market Price to Net Income Ratio|Price to Earnings Ratio FATE|WHWK: Company Value to Net Income|Price to Earnings Ratio TCRX (TScan Therapeutics Inc)|Business Payback Period Champions Oncology Inc|P/E Multiple XBIT (XBiotech Inc.)|Company Value to Net Income CVM|OS Therapies Inc. - P/E Multiple|RADX - P/E Multiple|ARTV: P/E Multiple|ANL: Market Price to Net Income Ratio|Price to Earnings Ratio VERU|TPST: Company Value to Net Income|Price to Earnings Ratio xiliotx.com (XLO)|Renovaro - Price to Earnings Multiple|Price to Earnings Ratio Mural Oncology MURA|KAPA - Price to Earnings Ratio|OKUR - Price to Earnings Ratio|GDTC - P/E Multiple|Curis, Inc. (CRIS) - Price to Earnings Ratio|Price to Earnings Ratio Apollomics, Inc.|Price to Earnings Ratio THAR|Price to Earnings Multiple ADVB (Advanced Biomed)|Price to Earnings Ratio GNPX (Genprex, Inc)|CLDI: Market Cap to Net Income|Price to Earnings Ratio sunshinebiopharma.com SBFM|XBIO - Price to Earnings Ratio|SLRX: Price to Earnings Ratio|Purple Biotech - Market Price to Net Income Ratio|American Oncology Network (AONC) - Price to Earnings Ratio|Checkpoint Therapeutics, Inc (CKPT) - P/E Multiple|Price to Earnings Ratio Elevation Oncology, Inc.|ICAD: Company Value to Net Income|Price to Earnings Ratio ikenaoncology.com (IKNA)|Price to Earnings Ratio NTBL (Notable Labs, Ltd.)|P/E Multiple VIRX (viracta.com)|MOR - Price to Earnings Ratio|NAYA - Price to Earnings Ratio|Market Cap to Net Income AAPGV